Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9948035 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2NPC1TP53POLBNFKB1 | |
| SCHEMBL9948422 | 0.92 | — | — | |
| SCHEMBL9948424 | 0.92 | — | — | |
| SCHEMBL9948039 | 0.88 | SMN1; SMN2 (0.38) | SMN1; SMN2NPC1TP53POLBNFKB1 | |
| SCHEMBL9947892 | 0.84 | APLNR (0.36) | — | |
| SCHEMBL9948184 | 0.84 | — | — | |
| SCHEMBL9947890 | 0.84 | APLNR (0.36) | — | |
| SCHEMBL9948189 | 0.84 | — | — | |
| SCHEMBL9947732 | 0.83 | SMN1; SMN2 (0.39) | SMN1; SMN2NPC1TP53POLBNFKB1 | |
| SCHEMBL15435592 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315493-B2 | Phenylpyridine derivative and drug containing same | KOWA COMPANY, LTD. (JP) | 2016-04-19 | — | — | US | disclosed |
| US-8778954-B2 | Phenylpyridine derivative and medicinal agent comprising same | KOWA COMPANY, LTD. (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20140011823-A1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND DRUG CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2014-01-09 | — | — | US | disclosed |
| US-20120165353-A1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND MEDICINAL AGENT COMPRISING SAME | KOWA COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011823-A1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND DRUG CONTAINING SAME | AGTR2, AGTR1, PPARD | SMN1; SMN2 4689/4885NPC1 2133/4885TP53 4493/4885 |
| US-20120165353-A1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND MEDICINAL AGENT COMPRISING SAME | AGTR2, AGTR1, PPARD | SMN1; SMN2 4773/4885NPC1 2655/4885TP53 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.